☰

Colin A. Flaveny, Ph.D. - Publications

Affiliations: 
2010 Pennsylvania State University, State College, PA, United States 
Area:
Molecular Biology, Toxicology
Tree Info Grants Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, et al. . Pharmacological Reviews. PMID 37586884 DOI: 10.1124/pharmrev.121.000436  0.354
2021 Musicant AM, Parag-Sharma K, Gong W, Sengupta M, Chatterjee A, Henry EC, Tsai YH, Hayward MC, Sheth S, Betancourt R, Hackman TG, Padilla RJ, Parker JS, Giudice J, Flaveny CA, et al. CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition. Cell Reports. 34: 108768. PMID 33626346 DOI: 10.1016/j.celrep.2021.108768  0.348
2020 Welch RD, Billon C, Kameric A, Burris TP, Flaveny CA. Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice. Plos One. 15: e0227720. PMID 32407314 DOI: 10.1371/Journal.Pone.0227720  0.322
2019 Carpenter KJ, Valfort AC, Steinauer N, Chatterjee A, Abuirqeba S, Majidi S, Sengupta M, Di Paolo RJ, Shornick LP, Zhang J, Flaveny CA. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer. Scientific Reports. 9: 19530. PMID 31863071 DOI: 10.1038/S41598-019-56038-1  0.381
2019 Sur S, Nakanishi H, Flaveny C, Ippolito JE, McHowat J, Ford DA, Ray RB. Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract. Cell Communication and Signaling : Ccs. 17: 131. PMID 31638999 DOI: 10.1186/S12964-019-0447-Y  0.371
2019 Musicant AM, Sharma KP, Henry EC, Tasoulas J, Padilla R, Sengupta M, Flaveny C, Amelio AL. Abstract 874: The CRTC1/MAML2 oncogene induces a PGC-1a splice variant that sensitizes mucoepidermoid carcinoma cells to PPARg inhibition Cancer Research. 79: 874-874. DOI: 10.1158/1538-7445.Am2019-874  0.355
2018 May A, Abuirqeba S, Hamilton Z, Flaveny C, Siddiqui S. MP70-14 REGULATION OF PROSTATE CANCER METABOLISM AND INVASIVENESS BY THE LIVER X RECEPTOR Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2258  0.339
2017 Welch RD, Billon C, Valfort AC, Burris TP, Flaveny CA. Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle. Scientific Reports. 7: 17142. PMID 29215066 DOI: 10.1038/S41598-017-17496-7  0.305
2017 Welch RD, Flaveny CA. REV-ERB and ROR: therapeutic targets for treating myopathies. Physical Biology. 14: 045002. PMID 28586319 DOI: 10.1088/1478-3975/14/4/045002  0.302
2015 Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell. 28: 42-56. PMID 26120082 DOI: 10.1016/J.Ccell.2015.05.007  0.509
2014 Li B, Flaveny CA, Giambelli C, Fei DL, Han L, Hang BI, Bai F, Pei XH, Nose V, Burlingame O, Capobianco AJ, Orton D, Lee E, Robbins DJ. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. Plos One. 9: e101969. PMID 25003333 DOI: 10.1371/Journal.Pone.0101969  0.362
2014 Li B, Fei DL, Flaveny CA, Dahmane N, Baubet V, Wang Z, Bai F, Pei XH, Rodriguez-Blanco J, Hang B, Orton D, Han L, Wang B, Capobianco AJ, Lee E, et al. Pyrvinium attenuates Hedgehog signaling downstream of smoothened. Cancer Research. 74: 4811-21. PMID 24994715 DOI: 10.1158/0008-5472.Can-14-0317  0.397
2012 Fei DL, Sanchez-Mejias A, Wang Z, Flaveny C, Long J, Singh S, Rodriguez-Blanco J, Tokhunts R, Giambelli C, Briegel KJ, Schulz WA, Gandolfi AJ, Karagas M, Zimmers TA, Jorda M, et al. Hedgehog signaling regulates bladder cancer growth and tumorigenicity. Cancer Research. 72: 4449-58. PMID 22815529 DOI: 10.1158/0008-5472.Can-11-4123  0.396
2011 Murray IA, Flaveny CA, Chiaro CR, Sharma AK, Tanos RS, Schroeder JC, Amin SG, Bisson WH, Kolluri SK, Perdew GH. Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3',4'-dimethoxy-α-naphthoflavone. Molecular Pharmacology. 79: 508-19. PMID 21127131 DOI: 10.1124/Mol.110.069369  0.793
2010 Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR, Flaveny CA, Perdew GH, Denison MS, Schultz PG, Cooke MP. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science (New York, N.Y.). 329: 1345-8. PMID 20688981 DOI: 10.1126/Science.1191536  0.6
2010 Murray IA, Krishnegowda G, DiNatale BC, Flaveny C, Chiaro C, Lin JM, Sharma AK, Amin S, Perdew GH. Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. Chemical Research in Toxicology. 23: 955-66. PMID 20423157 DOI: 10.1021/Tx100045H  0.799
2010 DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicological Sciences : An Official Journal of the Society of Toxicology. 115: 89-97. PMID 20106948 DOI: 10.1093/Toxsci/Kfq024  0.707
2010 Flaveny CA, Murray IA, Perdew GH. Differential gene regulation by the human and mouse aryl hydrocarbon receptor. Toxicological Sciences : An Official Journal of the Society of Toxicology. 114: 217-25. PMID 20044593 DOI: 10.1093/Toxsci/Kfp308  0.68
2010 Schroeder JC, Dinatale BC, Murray IA, Flaveny CA, Liu Q, Laurenzana EM, Lin JM, Strom SC, Omiecinski CJ, Amin S, Perdew GH. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry. 49: 393-400. PMID 20000589 DOI: 10.1021/Bi901786X  0.79
2010 Murray IA, Morales JL, Flaveny CA, Dinatale BC, Chiaro C, Gowdahalli K, Amin S, Perdew GH. Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity. Molecular Pharmacology. 77: 247-54. PMID 19903824 DOI: 10.1124/Mol.109.061788  0.773
2010 Murray IA, Flaveny CA, DiNatale BC, Chairo CR, Schroeder JC, Kusnadi A, Perdew GH. Antagonism of aryl hydrocarbon receptor signaling by 6,2',4'-trimethoxyflavone. The Journal of Pharmacology and Experimental Therapeutics. 332: 135-44. PMID 19828881 DOI: 10.1124/Jpet.109.158261  0.774
2009 Flaveny CA, Perdew GH. Transgenic Humanized AHR Mouse Reveals Differences between Human and Mouse AHR Ligand Selectivity. Molecular and Cellular Pharmacology. 1: 119-123. PMID 20419055 DOI: 10.4255/Mcpharmacol.09.15  0.711
2009 Flaveny C, Perdew GH, Miller CA. The Aryl-hydrocarbon receptor does not require the p23 co-chaperone for ligand binding and target gene expression in vivo. Toxicology Letters. 189: 57-62. PMID 19447165 DOI: 10.1016/J.Toxlet.2009.05.002  0.679
2009 Patel RD, Murray IA, Flaveny CA, Kusnadi A, Perdew GH. Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Laboratory Investigation; a Journal of Technical Methods and Pathology. 89: 695-707. PMID 19333233 DOI: 10.1038/Labinvest.2009.24  0.706
2009 Flaveny CA, Murray IA, Chiaro CR, Perdew GH. Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice. Molecular Pharmacology. 75: 1412-20. PMID 19299563 DOI: 10.1124/Mol.109.054825  0.705
2008 Flaveny C, Reen RK, Kusnadi A, Perdew GH. The mouse and human Ah receptor differ in recognition of LXXLL motifs. Archives of Biochemistry and Biophysics. 471: 215-23. PMID 18242161 DOI: 10.1016/J.Abb.2008.01.014  0.623
Show low-probability matches.